Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Prime Medicine (PRME) Leases (2021 - 2025)

Prime Medicine filings provide 5 years of Leases readings, the most recent being $126.2 million for Q4 2025.

  • On a quarterly basis, Leases rose 167.57% to $126.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $126.2 million, a 167.57% increase, with the full-year FY2025 number at $126.2 million, up 167.57% from a year prior.
  • Leases hit $126.2 million in Q4 2025 for Prime Medicine, up from $117.9 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $126.2 million in Q4 2025 to a low of $10.7 million in Q4 2021.
  • Median Leases over the past 5 years was $29.5 million (2022), compared with a mean of $47.8 million.
  • Biggest five-year swings in Leases: crashed 57.7% in 2024 and later soared 963.74% in 2025.
  • Prime Medicine's Leases stood at $10.7 million in 2021, then surged by 174.94% to $29.5 million in 2022, then tumbled by 52.81% to $13.9 million in 2023, then skyrocketed by 238.25% to $47.2 million in 2024, then skyrocketed by 167.57% to $126.2 million in 2025.
  • The last three reported values for Leases were $126.2 million (Q4 2025), $117.9 million (Q3 2025), and $120.2 million (Q2 2025) per Business Quant data.